|
|
||||||||
Unité de recherche, Centre de Pneumologie, Hôpital Laval. Institut de cardiologie et de pneumologie de l'Université Laval, Canada
CORRESPONDENCE: Y. Cormier, Hôpital Laval, 2725 Chemin Ste-Foy, Ste-Foy, Québec, Canada , G1V 4G5. Fax: 1 4186564762. E-mail: yvon.cormier@med.ulaval.ca
Keywords: apoptosis, inflammation, lung, lymphocytes
Received: October 2, 2001
Accepted October 2, 2002
| Abstract |
|---|
|
|
|---|
The percentage of apoptotic lymphocytes was significantly lower in HP patients than in normal patients (37.4±3.4 versus 56.5±5.5% for Annexin V and propidium iodine detection methods and 0.4±0.1 versus 1.0±0.2% for dUTP nick end-labelling technique (TUNEL)). The proportion of bronchoalveolar lavage (BAL) lymphocytes positive for Fas antigen was significantly higher in HP patients than in normal subjects (71.7±5.4 versus 50.4±9.0%). However, no significant difference was found in the proportion of BAL lymphocytes positive for Fas ligand (FasL) between the two groups. Soluble Fas (sFas) levels in the BAL fluid of the patients and normals were 80.5±8.5 pg·mL1 and 23.2±3.1 pg·mL1, respectively. A positive correlation was found between the percentage of BAL lymphocytes and the levels of sFas for the total subjects but not within the separate study groups. The intracellular quantity of the inducible anti-apoptotic gene Bcl-xL product was significantly higher in the pulmonary lymphocytes of HP patients than in lymphocytes of the control, while no difference was found for constitutive anti-apoptotic protein (Bcl2).
In conclusion, the apoptosis of pulmonary lymphocytes is lower in hypersensitivity pneumonitis than in normal subjects. This could be explained, at least in part, by an increase of soluble Fas, the anti-apoptic gene, and Bcl-xL.
Hypersensitivity pneumonitis (HP), an antigen-induced inflammatory lung disease, represents a situation where the immune regulation is disrupted, which leads to the accumulation of large numbers of lymphocytes in the lung 1. There are three possible mechanisms (not mutually exclusive) by which lymphocytes accumulate in the lung in HP: 1) increased recruitment 2; 2) local proliferation 3, 4; and 3) increased survival (decreased apoptosis). This study addresses the issue of decreased lung lymphocyte apoptosis in HP.
During an immune response against foreign antigens, clonal expansion of immunocompetent cells is necessary to mount effective protection. These cells must eventually die off in order to maintain tissue homeostasis 5. Regulation of cell survival is therefore crucial in limiting the accumulation of potentially harmful cells in the lung. Apoptosis is a physiological, genetically controlled, cellular response to external and internal stimuli whose purpose is to eliminate unwanted cells while preventing damage to surrounding cells or tissue 6. Apoptosis is often associated with the cross-linking between Fas antigen (Fas or CD95) and its physiological ligand (FasL or CD95L) through cell-to-cell interactions 7. This pathway can be inhibited by the soluble form of Fas (sFas) 8. These interactions are often implicated in the regulation of inflammatory cell death, particularly the lymphocytes 9. Apoptosis of CD4+ T-cells is primarily induced by Fas whereas death of CD8+ T-cells is induced by tumor necrosis factor type 1 receptor (TNFR1) and type 2 receptor (TNFR2) 10.
The Bcl-2 gene family regulates the apoptotic process through the balance of pro-apoptotic (Bax, Bcl-xS) and anti-apoptotic products (Bcl-2, Bcl-xL) 11. Several cytokines can also affect apoptosis. For example, interleukin (IL)-2 can inhibit inflammatory cell apoptosis 12. This cytokine is upregulated in HP 13.
Another mechanism implicated in the survival of lymphocytes is the B7-CD28 costimulation pathway. CD28, a molecule carried by lymphocytes, is a ligand for B7-1 and B7-2 receptors on antigen-presenting cells (APC), such as the alveolar macrophage 14. CD28 stimulation increases the expression of Bcl-xL and the production of IL-2 through lymphocytes 15. It has been shown recently that the B7-CD28 costimulation pathway is involved in HP 16, 17. This pathway could therefore contribute to the accumulation of lymphocytes in HP by an upregulation of certain lymphocyte-specific anti-apoptotic factors.
Having hypothesised that the accumulation of lymphocytes in the lungs of HP could result from decreased apoptosis, the present study was performed to quantify and characterise the apoptosis of lung lymphocytes recovered by bronchoalveolar lavage (BAL) from normal subjects and HP patients.
| Materials and methods |
|---|
|
|
|---|
Bronchoalveolar lavage
BAL was obtained by standard fibroscopy. For the HP patients, a total of 300 mL of sterile 0.9% saline solution was instilled in the middle lobe or the lingula in 50 mL aliquots. Since normal subjects have low BAL lymphocyte numbers, they underwent a double lavage (240 mL in the right middle lobe and 240 mL in the lingula). Each aliquot was sequentially aspirated and the recovered volume measured. BAL cells were washed with Hank's balanced salt solution, resuspended in Rosswell Park Memorial Institute 1640 medium (Canadian Life Technology, Burlington, ON, Canada) supplemented with 10% foetal bovine serum and 1% penicillin-streptomycin, and counted with a haemocytometer. BAL cell viability (trypan blue exclusion) ranged from 9099% (average of 95.9%). Differential counts for the different inflammatory cells (lymphocytes, macrophages, neutrophils and eosinophils) were performed on a cytospin preparation stained with Diff-Quik (Baxter Diagnostics, Mississauga, ON, Canada). The isolation of BAL lymphocytes was performed using the standard method using a nylon-wool column 18. Using this technique an average of 92% pure lymphocytes was recovered (range 8595%).
Annexin V and propidium iodine
The BAL cells were stained using an Apoptosis Detection kit (R&D System, Minneapolis, MN, USA), according to the manufacturer's instruction. Cytometry analysis of the cells was performed immediately using an EPICS® ELITE ESP flow cytometer (Beckman-coulter, Miami, FL, USA). A minimum of 10,000 cells were counted per assay. The appropriate controls were carried out. Annexin-positive and propidium iodine (PI)-negative cells were considered in early apoptosis.
Analysisofinsitudeoxyribonucleicacid fragmentation
Paraformaldehyde-fixed air-dried cytospin preparations were stained by the terminal deoxinucleotidyl transferase (TdT) mediated dUTP nick end-labelling technique (TUNEL) using recombinant TdT (rTdT) 19. For the assay, the cytospin preparation was fixed for 30 min in a fresh solution of 4% paraformaldehyde in a phosphate buffer solution (PBS) (pH 7.4). The slides were then washed twice with PBS and incubated in a permeabilisation solution (0.1% Triton X-100 in 0.1% sodium citrate) for 2 min on ice (4°C). After another wash with PBS, the area around the sample was dried and a 20 µL drop of enzyme solution (0.3 U rTdT (Canadian Life Technology), 6x1010 M biotin-16-dUTP (Roche Diagnostics Canada, Laval, QUE, Canada), 0.1 M potassium cacodylate (pH 7.2), 2x103 M CoCl2, 2x104 M dithiothreitol) was added and a cover slip was placed on the sample. The preparation was incubated for 60 min at 37°C in a humidified chamber. After three washes in PBS, 13.5 nM of conjugated fluorescent dye streptavidine-Alexa 488TM (Molecular probes, Eugene, OR, USA) was added in a 20 µL drop and kept in the dark for 20 min at 4°C. ProlongTM Antifade kit (Molecular probes) was used (according to the manufacturer's protocol) to mount the slides and to avoid fluorescence quenching. For the negative control, rTdT was replaced with enzyme buffer and for the positive control, a pre-incubation with 5U of Dnase 1 (Amersham Pharmacia Biotech, Piscataway, NJ, USA) was performed immediately before the incubation with the enzyme solution. The count was carried out using an epifluorescence microscope (Nikon Eclipse 6600; Nikon Canada Inc., Quebec, QE, Canada) with the appropriate filter (Nikon filter B2-A, ex: 450-490, em: 505). A minimum of 300 cells were counted on each slide. Two criteria were used to qualify a positive cell (in a late phase of apoptosis): 1) bright green fluorescence on nuclei; and 2) morphological feature of a cell in apoptosis.
Antibodies
Fluoresecin isothiocynate labelled Bcl-2/100 (mouse immunoglobulin (Ig)G1 antihuman Bcl-2-FITC), Dx2 (mouse IgG1, antihuman CD95-PE (Fas)), NOK-1 (mouse IgG1 antihuman CD95L-PE (FasL)), 2H12 (mouse antihuman Bcl-xL), HIT3a (mouse IgG1 antihuman CD3-PerCP) and the isotype control (mouse IgG1-FITC, mouse IgG1-PE and mouse IgG1-PerCP) were purchased from Pharmingen (San Diego, CA, USA).
Flow cytometry for Fas, FasL and Bcl-2
A total of 2.0x106 BAL cells were resuspended in 200 µL of PBS+1% bovine serum albumin. A batch of cells (5x105 cell·501 µL) were labelled with 2 µL of anti-CD3 or 2 µL of isotype control and placed on ice (4°C) for 45 min. The same protocol was used to label a sample of cells 1.0x106 with anti-CD95 (2 µL) and anti-CD95L (2 µL) and specific isotype controls. The remaining cells (5x105 cell in 50 µL) were permeabilised using a commercial kit (Perm Kit; Pharmingen) before the incubation with anti-Bcl-2 antibodies and its specific isotype control (2 µL of the antibodies, 45 min on ice).
Evaluation of soluble Fas in bronchoalveolar lavage fluid
The quantification of sFas in BAL fluids was carried out by a sandwich-type enzyme-linked immunosorbent assay (ELISA) using an OptEIA Human Fas kit (Pharmingen) according to the protocol provided by the manufacturer.
Preparation of the samples for Western blot
A total of 1x106 BAL lymphocytes were purified on nylon-wool columns and resuspended in 20 µL of lysis buffer (10 mM Tris-HCl (pH 7.4)), 150 mM NaCl, 2 mM ethylenediamine tetraacetic acid (EDTA), 2% triton X-100, 1% of mixture of protease inhibitor (2 mM EDTA, 2 mM polymethylsulfonyl flouride, 1 µg·mL1 of aprotinin, 1 µg·mL1 of leupeptine, all from Sigma) and 20 µL of 2x loading buffer (200 mM Tris HCl (pH 6.8), 20% glycerol, 2% sodium dodeclysulphate (SDS), 0.0005% bromophenol blue, 10% 2-mercapto-ethanol). The mixture was denatured by heating at 100°C for 5 min and then centrifuged at 10,000xg for 1 min in order to precipitate phospholipids present in the samples. The supernatant (40 µL) was frozen at -70°C until used.
Western blot for Bcl-xL
The samples (1x106 purified BAL lymphocytes) were separated on a 12% polyacrylamide gel (SDS-perflourocarbon-associated gas exchange (PAGE)) and transferred onto a polyvinylidene difluoride membrane. The blot was blocked for 1 h at room temperature with blocking buffer (5% fat-free dry milk, 0.05% tween 20 in tris buffered saline) and probed for 1 h with a monoclonal antibody to Bcl-xL used at a dilution of 1:100 in the blocking buffer. The secondary probe (1:100 in blocking buffer), with a goat IgG antimouse IgG horseradish peroxidase (Cedarlane, ON, USA), was detected by chemiluminescence using enhanced chemiluminescence (Amersham Pharmacia Biotech). BAL alveolar macrophages were used as the positive control. The densitometric analysis was performed using Scion Image (Scion Coorperation, MO, USA).
Statistical analysis
Results are expressed as mean±sem unless otherwise stated. All data were analysed using t-test except for the following: 1) finding as correlation between the percentage of BAL lymphocytes and the concentration of sFAS molecules where a Spearman rank correlation test was used; and 2) working out the proportion of positive lymphocytes where a Mann-Whitney U-test was applied. A p-value of <0.05 was considered significant.
| Results |
|---|
|
|
|---|
|
|
50% higher in HP patients than in normal subjects (68±5.4% (n=18) and 46.7±9.0 (n=9), respectively, p=0.004). This result is in agreement with the data of Agostini et al. 21. The proportion of positive lymphocytes for FasL was also determined. As shown in figure 2b
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
The results cannot quantify the relative importance of apoptosis in the maintenance of pulmonary inflammation in HP, but suggest it could be a significant one. Although all of the tests were not performed on the BAL cells of all subjects in each group, the marked differences between the groups is clearly shown by the studies performed.
The presence of fewer apoptotic lymphocytes and an increase in the number that are Fas positive at first seems contradictory. The anticipated higher percentage of apoptosis associated with Fas expression was probably overshadowed by the increased concentration of the soluble Fas and by the increased intracellular Bcl-xL. The ligation of Fas/FasL is a cell-to-cell interaction often implicated in the initiation of apoptosis. sFas binds to FasL, therefore limiting the number of this pro-apoptotic receptor on activated lymphocytes 22. Shedding of sFas is an inflammatory mechanism by which the immune system can prolong the viability of lung lymphocytes and this is what appears to happen in HP. The possibility of a failure in the initiation of the apoptosis by the Fas/FasL cannot be eliminated. For example, an overproduction of the Bcl-2 protein in lymphocytes in culture (of Jurkat type) inhibits the Fas-induced apoptosis 23. Also, an overproduction of Bcl-xL in MCF7 cells (humoral epithelial cells) expressing Fas makes these cells resistant to Fas-induced apoptosis 24.
Although this study confirms that pulmonary lymphocytes in HP patients express more Bcl-xL than those from normal subject, it is unknown whether the intracellular level of Bcl-2 is increased. A positive cell can contain an unknown quantity of Bcl-2 (limit of detection of the test to a maximum concentration). Western blot techniques will be needed to further evaluate the implication of the Bcl-2 protein in the reduction of apoptosis in HP.
The increase in the intracellular levels of Bcl-xL of the BAL lymphocytes in HP could be related to the increase in costimulation via the B7-CD28 pathway. Indeed, as previously mentioned, this pathway is unregulated in HP. An increase in costimulation B7-CD28 is known to increase resistance to lymphocyte apoptosis mediated via the intracellular increase of the Bcl-xL protein and by increased expression of IL-2, a survival factor for these cells 15.
An interesting question raised by the results of this study is whether the reduction in the apoptosis of the BAL lymphocytes in HP is due to an intrinsic modulation of the cells themselves and/or to the pulmonary micro-environment they were collected from. It is possible that other anti-apoptotic factors, other than Bcl-xL and sFas, present in the pulmonary environment, could participate in the decrease of lymphocyte apoptosis.
Further studies are needed to elucidate the mechanisms involved in the control of lymphocyte survival in HP. The effect of the micro-environment would require in vitro studies looking at the effect of anti-apoptotic cytokines on BAL lymphocytes. For example, purified BAL lymphocytes of HP patients and control subjects could be cultured with Fas agonist and IL-2 in order to evaluate these different stimulations on the lymphocyte apoptosis in time. Further work is also needed to investigate the relevance of these findings to the development of HP because it has been shown that lymphocytosis also occurs in the lungs of exposed individuals who remain asymptomatic 25.
| Conclusions |
|---|
|
|
|---|
| Acknowledgements |
|---|
|
|
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
A. Paranjpe, L.C.F. Bordador, M.-y. Wang, W.R. Hume, and A. Jewett Resin Monomer 2-Hydroxyethyl Methacrylate (HEMA) is a Potent Inducer of Apoptotic Cell Death in Human and Mouse Cells J. Dent. Res., February 1, 2005; 84(2): 172 - 177. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |